We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm.The outlay gives J&J control of preclinical prospects designed to evade the body’s immune system...